Lepu Biopharma (HKG:2157) completed a filing with the China Securities Regulatory Commission for the conversion of its 54,268,364 unlisted domestic shares and their issuance as H shares on the Hong Kong bourse, according to a Wednesday filing with the exchange.
Shares in the biopharmaceutical company rose 2% during morning trading on Thursday.